Nucleic acid immunization protects dogs against challenge with virulent canine parvovirus.
Nucleic acid vaccines (NAVs) use expression vectors encoding one or more antigen genes to transfect host cells inducing both humoral and cellular immunity against the expressed antigen. NAV offers major advantages over conventional vaccines for the protection of humans and animals. This study shows that a plasmid DNA (pGT36VP1) encoding the full length VP1 region of canine parvovirus (CPV) induces immunity that protects dogs against challenge with virulent virus. Five dogs without anti-CPV antibodies were injected at 9 months of age with increasing doses of pGT36VP1 or saline. NAV vaccinated dogs showed an increase of serum IgG titer starting 1 week post-injection which peaked at week 2 and remained detectable for at least 14 weeks. A second dose of NAV resulted in an anamnestic response within 1 week. IgG titers peaked at week 3 and 4 after the second injection. All pGT36VP1 vaccinated dogs were protected against infection after virulent CPV challenge regardless of dose and the unvaccinated control dog was fully susceptible. This study demonstrated for the first time that a NAV can protect dogs against an infectious disease.
Jiang
W
W
Scott-Ritchey Research Center, College of Veterinary Medicine, Auburn University, AL 36849, USA.
Baker
H J
HJ
Swango
L J
LJ
Schorr
J
J
Self
M J
MJ
Smith
B F
BF
D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis / Q000097:blood; D002213:Capsid / Q000235:genetics / Q000276:immunology; D036022:Capsid Proteins; D002415:Cats; D003001:Cloning, Molecular; D004283:Dog Diseases / Q000517:prevention & control* / Q000821:virology; D004285:Dogs; D007074:Immunoglobulin G / Q000096:biosynthesis / Q000097:blood; D009500:Neutralization Tests; D010322:Parvoviridae Infections / Q000517:prevention & control* / Q000662:veterinary*; D017993:Parvovirus, Canine / Q000235:genetics / Q000276:immunology* / Q000472:pathogenicity; D016133:Polymerase Chain Reaction; D014611:Vaccination; D019444:Vaccines, DNA / Q000235:genetics / Q000627:therapeutic use*; D014774:Virulence
D000914:Antibodies, Viral; D036022:Capsid Proteins; D007074:Immunoglobulin G; D019444:Vaccines, DNA; C095547:capsid protein VP1, parvovirus B19